Raymond, E., Kulke, M., Qin, S., Schenker, M., Cubillo, A., Lou, W., … Fazio, N. (2017). The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors. In PANCREAS (Vol. 46, pp. 435–435). LIPPINCOTT WILLIAMS & WILKINS.

Raymond, Eric, Matthew Kulke, Shukui Qin, Michael Schenker, Antonio Cubillo, Wenhui Lou, Jiri Tomasek, et al. “The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors.” In PANCREAS, 46:435–435. LIPPINCOTT WILLIAMS & WILKINS, 2017.

Raymond E, Kulke M, Qin S, Schenker M, Cubillo A, Lou W, et al. The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors. In: PANCREAS. LIPPINCOTT WILLIAMS & WILKINS; 2017. p. 435–435.

Raymond, Eric, et al. “The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors.” PANCREAS, vol. 46, no. 3, LIPPINCOTT WILLIAMS & WILKINS, 2017, pp. 435–435.

Raymond E, Kulke M, Qin S, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu J, Racz K, Croitoru A, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein P, Ito T, Fernandez K, Rosbrook B, Fazio N. The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS; 2017. p. 435–435.